You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

À propos des lignes directrices

Displaying Guidelines

11 articles

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Document Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Mar 2025

Bone Health and Bone-Targeted Therapies for Prostate Cancer

Document Status: Current
ID: 3-14
Version: 3

Updated

Jun 2025

Effective Teaching Strategies and Methods for Cancer Patient Education

Document Status: Current
ID: GL 20-2
Version: 2

Apr 2025

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2024

Document Status: Current
ID: PET 2024-1

Mar 2025

Fluoropyrimidine Treatment in Patients with Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Guidance for Clinicians

Document Status: Current
Version: 2

Updated

Sep 2025

Follow-up for Cervical Cancer

Document Status: Current
ID: 4-16
Version: 3

Updated

May 2025

Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-Line Chemotherapy

Document Status: Current
ID: 7-13
Version: 2

Updated

Sep 2025

Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer

Document Status: Current
ID: GL 17-10 v2
Version: 2

Mar 2025

Role of Adjuvant Treatment in Resected Pancreatic Ductal Adenocarcinoma

Document Status: Current
ID: GL 2-33
Version: 2

Updated

Jun 2025

Systemic Treatment Emergency Preparedness Guidance Document

Document Status: Current

Updated

Aug 2025

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Document Status: Current

Mar 2025